PhenomeX to Participate in Upcoming Cell Biology Conferences

~ PhenomeX Inc., a functional cell biology company listed on the Nasdaq (CELL), has announced that it will be showcasing its latest optofluidic and proteomic technologies at two upcoming cell biology conferences.

At the Discovery on Target 2023 conference, held from September 25-27 in Boston, Genovac, a long-standing customer of PhenomeX and super user of the Beacon optofluidic technology, will lead a presentation featuring PhenomeX's Beacon platform. The presentation is entitled "Enhance and Expand Anti-ID Antibody Diversity and Affinity Through Genetic Immunization" and will be delivered by Andreas Weise, senior account manager at Genovac.

The Annual Festival of Biologics Basel Conference & Exhibition will also feature PhenomeX's optofluidic and proteomic technologies in booth #910. Jonathan Didier, senior field applications scientist at PhenomeX, will present "Rapid Discovery of Clinically Relevant Antibodies using the PhenomeX Beacon" as part of the Cell Culture & Upstream Processing conference track. Additionally, a poster presentation entitled "Rapid Discovery of Functional Human Memory B Cell-Derived Antibodies for SARS-CoV-2 Using the Beacon Optofluidic System" will be featured.

More on Boston Chron
PhenomeX is dedicated to advancing human health through its unique suite of high-throughput tools and services that offer unparalleled resolution and speed to accelerate discoveries that can profoundly improve the prevention and treatment of disease. Its award-winning platforms are used by researchers across the globe, including those at the top 15 global pharmaceutical companies and approximately 85% of leading U.S. comprehensive cancer centers. The company is also in the process of changing its name; all inquiries regarding Phenomenex, Inc. should be directed to their website.
Filed Under: Business

Show All News | Report Violation


Latest on Boston Chron